Experimenting
with
Synergy
|
The crystal structure of the autoinhibited
kinase domain of CaMKII. From top to bottom: The domain organization
of CaMKII and two views of the CaMKII dimer, rotated 90° from
each other. Molecule A is shown in green and molecule B is
shown in blue. The Ca2+/CaM binding residues are
shown in magenta and the rest of the regulatory segment is
shown in orange. Thr 286 is the residue that is autophosphorylated,
leading to Ca2+/CaM independence.
Many years of cell biology and biochemistry
have shown that a key player in this process is an enzyme that
transfers phosphate groups, the Ca2+/calmodulin-activated
protein kinase II (CaMKII). A large protein complex (about 600
kDa), it is made up of twelve individual polypeptide chains (i.e.,
a dodecamer). Each polypeptide contains a kinase domain, which
can phosphorylate downstream targets in the cell, and an “association
domain” that links the kinases together in the complete complex
(holoenzyme). These two domains are joined by a regulatory segment
that binds to the kinase and inhibits its activity, as well as
a linker domain of unknown function.
In the absence of Ca2+, the regulatory segment is bound
to the kinase, inhibiting its ability to phosphorylate its targets
(substrates) including itself (autophosphorylation). When calcium
enters the cell, it binds to the small protein calmodulin (CaM),
which in turn binds to the regulatory segment, releasing the kinase
activity. Underlying the ability of this protein complex to transduce
Ca2+
signals is a system, based on the autophosphorylation of the regulatory
segment, that allows the kinase activity to be initially dependent
on Ca2+/CaM and then to become independent in response
to an increasing Ca2+ oscillation frequency, thereby
allowing the phosphorylation to persist even after the calcium
signal is over.
The group solved the crystal structure of the isolated kinase
domain and regulatory segment of CaMKII from data obtained at ALS
Beamline 8.2.2. Members
were surprised to find that pairs of neighboring kinase domains
form dimers where the active site of the kinase domain is blocked
by a coiled-coil (two alpha-helix coils coiled together) formed
by the regulatory segments. The significance of the dimer structure
was suggested by biophysical measurements of Ca2+/CaM
binding to the holoenzyme. The measurements showed that the activation
of the holoenzyme dodecamer is highly cooperative, thereby suggesting
that when Ca2+/CaM binds to the kinase, it releases
the activity of more than one kinase domain.
Models of the holoenzyme structure and activation
using small-angle
x-ray scattering (SAXS) data. Left: A rigid body modeling scheme using
data from SAXS experiments resulted in a model of the CaMKII
holoenzyme. Right: Ab initio models
agree well with the rigid modeling results.
The new structure provides an answer for why this happens: When
Ca2+/CaM binds to one inhibiting regulatory segment,
it releases its dimer pair at the same time. This insight formed
the basis for a model of CaMKII activation by Ca2+/CaM.
In its resting state, the CaMKII holoenzyme is a tightly packed
and autoinhibited assembly that cannot autophosphorylate. When
Ca2+/CaM is added, however,
the kinase domains are disrupted and the complex converts into
an activated state that is capable of autophosphorylation and
Ca2+/CaM-independent activity.
Addition of Ca2+/CaM to the holoenzyme causes a dramatic increase
in the radius of gyration of the protein complex.
Because the holoenzyme proved resistant to structural characterization
with crystallography, the collaborators turned to small-angle x-ray
scattering (SAXS) at the new SIBYLS beamline (12.3.1). The combination
of high-intensity SAXS and crystallography allowed the group to
build a model of the holoenzyme structure that was consistent with
their crystal structure and their biochemical results. The SAXS
model revealed that the kinase holoenzyme is a compact flattened
disc about 220 Å in diameter. The addition of Ca2+/CaM
to the holoenzyme increases the diameter of the complex by almost
25 Å, suggesting
that this addition changes the complex into a much looser association
of kinase domains.
Research conducted by O.S. Rosenberg (University of California,
Berkeley; Howard Hughes Medical Institute; and Yale University
School of Medicine); S. Deindl and R.-J. Sung (University of California,
Berkeley, and Howard Hughes Medical Institute); A.C. Nairn (Yale
University School of Medicine); and J. Kuriyan (University of California,
Berkeley; Howard Hughes Medical Institute; and Berkeley Lab).
Research funding: National Institutes of Health through the Yale
School of Medicine Medical Scientist Training Program and the Howard
Hughes Medical Institute. Operation of the ALS is supported by
the U.S. Department of Energy, Office of Basic Energy Sciences.
Publication about this research: O.S. Rosenberg, S. Deindl, R.-J.
Sung, A.C. Nairn, and J. Kuriyan, “Structure
of the autoinhibited kinase domain of CaMKII and SAXS analysis
of the holoenzyme,” Cell 123, 849
(2005).
ALSNews
Vol. 265, May 31, 2006 |